InnovationRx is your weekly healthcare news roundup. To receive it in your inbox, subscribe here.
On J. P. Morgan Healthcare’s last day (and the only day without rain) last week, I had the opportunity to sit down with Pitchbook analysts Rebecca Springer and Aaron DeGagne to tell them some of the key trends at the convention and what they would be. of the healthcare industry in the coming months.
One thing that caught DeWine’s attention: Element Bioscience’s announcement to reduce the value of part of its genomic sequencing to $200. DeGagne called this one of the main announcements of the week and in the coming months will observe the reaction of its competitors as well as the after-effects of less expensive genome sequencing. “The sequencer war has just begun,” he told me.
One key domain that Springer is tracking is the expansion of number one businesses based on care and value, which is set to expand in the coming years. “I think there’s a lot of white dominance in this domain,” he says. The next five years, they’re going to have a lot of dominance to execute and possibly won’t collide. “After that, though, he expects things to start adjusting. “We’re going to start seeing consolidation. “
Springer also oversees startups that care about Medicaid patients. “It’s a bigger green field,” he says. Several corporations and organizations have presented at the conference, and she sees a high price tag for those corporations, despite some of the demanding situations of this patient population. “They have harder work, but more space. “
U. S. pharmaceutical giant Pfizer said on Tuesday it will distribute its entire portfolio of drugs and vaccines to low-income nonprofit countries, notably expanding on an earlier program, as the industry again comes under fire for its accessibility amid high drug prices. earnings
Learn here.
Reverse mergers: Two other biotech corporations have announced that they will participate in opposing merger deals to make them public. Elicio Therapeutics, which develops immunotherapies, will marry a wholly-owned subsidiary of Angion Biomedica Corp. in a stock transaction. Meanwhile, Aprinoia Therapeutics, which focuses on neurodegeneration, will merge with Ross Acquisition Corp II in a deal that values the combined company at $280 million.
Digital acquisition: Digital fitness company Blackford, which has developed a medical symbol research platform, announced this week that it will be acquired through Bayer.
Maternity care: Oula, a startup that aims to improve pregnancy and childbirth care, announced that it has raised a $19. 1 million Series A. The investment is intended to advance the company’s full-service pregnancy care.
R
Walgreens agreed to pay West Virginia $83 million to settle allegations that the drugstore chain contributed to the state’s opioid crisis.
The Executive Director of the Bill Foundation
Last week, the American Academy of Pediatrics released updated clinical rules on obesity that now face some setbacks, but are based on decades of research.
Researchers at MIT and Massachusetts General Hospital have developed a device learning style that can expect a lung cancer threat from a single CT scan.
UnitedHealth Group’s profit totaled $4700 million in the fourth quarter, as the fitness giant’s UnitedHealthcare plans and Optum fitness maintained growth.
The state of California is suing an organization of drug and insulin brand benefit managers for “illegal, unfair and deceptive” means to raise the price of the diabetes drug.
One of the demanding situations of Covid-19 treatment has been the speed at which the virus mutated, especially its spike protein. This immediate mutation rate has meant that several antibody treatments that were developed and stored lives early in the pandemic through corporations like Lilly, Vir and Regeneron no longer work. This led the researchers to look for tactics to make healing antibodies more durable compared to the immediate adaptation rate of SARS-CoV-2. This is especially important for immunocompromised people, as vaccines tend to be less effective. for this group.
That’s why a new discovery from the La Jolla Institute of Immunology may hold promise for long-term antibody progression. The researchers discovered “bivalent” antibodies that are effective in opposition to the first variants and now to the new variants of Omicron. The antibodies bind to two sites on the virus’ spike protein at once, which may make the two long-term treatments more effective and help advise the progression of more sustainable vaccines.
While 94% of seniors got their number one vaccine, only 39% got an updated bivalent booster dose. Along with the underutilization of the antiviral drug Paxlovid, this winter may be another one full of preventable deaths.
Learn here.
New studies show that a pregnancy with Covid infection increases the threat of death of the mother almost 8 times compared to those who are not infected.
Vaccine hesitancy is already a factor in treating covid, but the anti-vaccine sentiment surrounding it can also lead to vaccine hesitancy for diseases.
The CDC said Friday that a possible link has been known between the bivalent Pfizer-BioNTech Covid-19 vaccine and ischemic stroke in other people over 65. It is under investigation, but clinical substitution is not advised because researchers believe a real threat is unlikely to exist.
They have lost millions due to crypto scammers. This prosecutor is helping them get it back.
Stimulating Black Women in Physics with the Goal of Making a Big Bang in Business
As Boeing Fights for Its Airplane Business, Elon Musk Has Lunch in Space
The HIV vaccine evolved through Johnson
Taliban ban on women’s NGOs worsens public fitness crisis in Afghanistan (Science)
How Your First Contact with COVID Distorts Your Immunity (Nature)